PTAB institutes IPRs against Teva's thrice-weekly Copaxone

The Patent Trials and Appeals Board of the U.S. Patent and Trademark Office instituted inter partes review (IPR) proceedings challenging two patents that cover the thrice-weekly formulation of multiple sclerosis drug Copaxone glatiramer acetate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Mylan N.V. (NASDAQ:MYL) filed the IPR petitions against U.S. Patents Nos. 8,232,250 and 8,399,413 in February. Both patents expire in 2030 and claim methods of treating MS with a 40 mg dose of Copaxone three times per week. The patents are owned by Yeda Research & Development Co. Ltd. and are licensed to Teva. ...